Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ST6GAL1 | P15907 | 15/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29377374 | 1.00 | ST6GAL1 (0.56) | ST6GAL1TSHRGLA | |
| SCHEMBL29425217 | 1.00 | ST6GAL1 (0.56) | ST6GAL1TSHRGLA | |
| SCHEMBL4181237 | 0.95 | ST6GAL1 (0.56) | ST6GAL1TSHRGLA | |
| SCHEMBL607765 | 0.95 | ST6GAL1 (0.56) | ST6GAL1TSHRGLA | |
| SCHEMBL584780 | 0.95 | ST6GAL1 (0.56) | ST6GAL1TSHRGLA | |
| SCHEMBL29636269 | 0.95 | ST6GAL1 (0.56) | ST6GAL1TSHRGLA | |
| SCHEMBL23188753 | 0.93 | ST6GAL1 (0.49) | ST6GAL1TSHRGLA | |
| SCHEMBL122854 | 0.93 | ST6GAL1 (0.49) | ST6GAL1TSHRGLA | |
| SCHEMBL18812503 | 0.93 | ST6GAL1 (0.49) | ST6GAL1TSHRGLA | |
| SCHEMBL13210237 | 0.93 | ST6GAL1 (0.49) | ST6GAL1TSHRGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 191 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4702138-A1 | PRODUCTION OF A NEGATIVELY CHARGED OLIGOSACCHARIDE BY A CELL | Inbiose N.V. (BE) | 2026-03-04 | — | — | EP | claimed |
| US-20250197905-A1 | LEGIONAMINIC ACID GLYCOSYLTRANSFERASES FOR CHEMOENZYMATIC SYNTHESIS OF GLYCANS AND GLYCOCONJUGATES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-06-19 | — | — | US | claimed |
| CN-120020261-A | Method for total synthesis of N-glycan | 中国科学院上海药物研究所 | 2025-05-20 | — | — | CN | claimed |
| CN-119384513-A | Novel sialyltransferases for in vivo synthesis of LST-c | 帝斯曼知识产权资产管理有限公司 | 2025-01-28 | — | — | CN | claimed |
| WO-2024223815-A1 | PRODUCTION OF A NEGATIVELY CHARGED OLIGOSACCHARIDE BY A CELL | INBIOSE N.V. (BE) | 2024-10-31 | — | — | WO | claimed |
| EP-4448734-A1 | PRODUCTION OF ALPHA-1,3-FUCOSYLATED COMPOUNDS | Inbiose N.V. (BE) | 2024-10-23 | — | — | EP | claimed |
| EP-4448781-A1 | PRODUCTION OF ALPHA-1,4-FUCOSYLATED COMPOUNDS | Inbiose N.V. (BE) | 2024-10-23 | — | — | EP | claimed |
| EP-4370664-A1 | LACTO-N-BIOSE CONVERTING FUCOSYLTRANSFERASES | Inbiose N.V. (BE) | 2024-05-22 | — | — | EP | claimed |
| EP-4347856-A2 | METHODS FOR PRODUCING TRYPTAMINE DERIVATIVES | Octarine Bio ApS (DK) | 2024-04-10 | — | — | EP | claimed |
| CN-117222736-A | Cellular production of biological products | 因比奥斯公司 | 2023-12-12 | — | — | CN | claimed |
| WO-2023110994-A1 | PRODUCTION OF ALPHA-1,4-FUCOSYLATED COMPOUNDS | INBIOSE N.V. (BE) | 2023-06-22 | — | — | WO | claimed |
| EP-4192969-A1 | PRODUCTION OF AN OLIGOSACCHARIDE MIXTURE BY A CELL | Inbiose N.V. (BE) | 2023-06-14 | — | — | EP | claimed |
| EP-4192945-A1 | CELLULAR PRODUCTION OF SIALYLATED DI- AND/OR OLIGOSACCHARIDES | Inbiose N.V. (BE) | 2023-06-14 | — | — | EP | claimed |
| CN-116249781-A | Production of biological products containing GlcNAc in cells | 因比奥斯公司 | 2023-06-09 | — | — | CN | claimed |
| CN-116096911-A | Production of oligosaccharide mixtures by cells | 因比奥斯公司 | 2023-05-09 | — | — | CN | claimed |
| WO-2023285650-A1 | LACTO-N-BIOSE CONVERTING FUCOSYLTRANSFERASES | INBIOSE N.V. (BE) | 2023-01-19 | — | — | WO | claimed |
| CN-115552026-A | Enzymatic method for preparing CMP-Neu5Ac | 马克斯·普朗克科学促进学会 | 2022-12-30 | — | — | CN | claimed |
| WO-2022248635-A2 | METHODS FOR PRODUCING TRYPTAMINE DERIVATIVES. | OCTARINE BIO APS (DK) | 2022-12-01 | — | — | WO | claimed |
| WO-2022152915-A1 | EXTRACELLULAR PRODUCTION OF GLYCOSYLATED PRODUCTS | INBIOSE N.V. (BE) | 2022-07-21 | — | — | WO | claimed |
| CN-114207108-A | Genetically modified host cells producing glycosylated cannabinoids | 奥克塔林生物制剂公司 | 2022-03-18 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250197905-A1 | LEGIONAMINIC ACID GLYCOSYLTRANSFERASES FOR CHEMOENZYMATIC SYNTHESIS OF GLYCANS AND GLYCOCONJUGATES | FNTA, MAGT1, FNTB | ST6GAL1 30/4885TSHR 2722/4885GLA 451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.